Ligand ID: Y70


Drugbank ID:
DB08910
(Pomalidomide)


Indication:
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Get human targets for Y70 in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'Y70' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2Z_B_Y70B151_1
(CEREBLON ISOFORM 4)		6lzg ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ASN B 439
PRO B 507
PHE B 497
TYR A  41
1.62A18.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2Z_A_Y70A151_1
(CEREBLON ISOFORM 4)		6lzg ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 7
ASN B 439
PRO B 507
PHE B 497
TYR A  41
1.65A18.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2Z_B_Y70B151_1
(CEREBLON ISOFORM 4)		6m17 ACE2
RECEPTOR BINDING
DOMAIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ASN E 439
PRO E 507
PHE E 497
TYR B  41
1.66A18.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2Z_A_Y70A151_1
(CEREBLON ISOFORM 4)		6m17 ACE2
RECEPTOR BINDING
DOMAIN
(Homo
sapiens;
SARS-CoV-2)		4 / 7
ASN E 439
PRO E 507
PHE E 497
TYR B  41
1.71A18.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2Z_C_Y70C151_1
(CEREBLON ISOFORM 4)		6m17 ACE2
RECEPTOR BINDING
DOMAIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ASN E 439
PRO E 507
PHE E 497
TYR B  41
1.65A18.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2Z_C_Y70C151_1
(CEREBLON ISOFORM 4)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASN A 703
PHE A 753
TRP A 617
TYR A 619
1.76A9.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2Z_B_Y70B151_1
(CEREBLON ISOFORM 4)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
MET B1050
PHE B 888
TRP B 886
TYR A1047
1.66A7.26
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2Z_B_Y70B151_1
(CEREBLON ISOFORM 4)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
MET A1050
PHE A 888
TRP A 886
TYR C1047
1.66A7.26
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4TZU_B_Y70B505_1
(PROTEIN CEREBLON)		6w4h NSP16
(SARS-CoV-2)		4 / 7
HIS A6867
TRP A6922
PHE A6954
THR A6891
1.66A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4TZU_B_Y70B505_1
(PROTEIN CEREBLON)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
HIS A6867
TRP A6922
PHE A6954
THR A6891
1.62A19.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4TZU_B_Y70B505_1
(PROTEIN CEREBLON)		6w75 NSP16
(SARS-CoV-2)		4 / 7
HIS C6867
TRP C6922
PHE C6954
THR C6891
1.77A22.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4TZU_B_Y70B505_1
(PROTEIN CEREBLON)		6w75 NSP16
(SARS-CoV-2)		4 / 7
HIS A6867
TRP A6922
PHE A6954
THR A6891
1.67A22.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6H0F_E_Y70E502_0
(IKAROS (IKZF1)
PROTEIN CEREBLON)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLU F 290
HIS F 356
TRP F 301
ASN F 269
GLY F 295
1.80A14.95
15.70
None
None
CL  F 401 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6H0F_H_Y70H502_0
(IKAROS (IKZF1)
PROTEIN CEREBLON)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLU B 290
HIS B 356
TRP B 301
ASN B 269
GLY B 295
1.78A14.95
15.70
None
None
CL  B 401 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6H0F_K_Y70K502_0
(IKAROS (IKZF1)
PROTEIN CEREBLON)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLU B 290
HIS B 356
TRP B 301
ASN B 269
GLY B 295
1.80A14.95
15.70
None
None
CL  B 401 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6H0F_H_Y70H502_0
(IKAROS (IKZF1)
PROTEIN CEREBLON)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLU F 290
HIS F 356
TRP F 301
ASN F 269
GLY F 295
1.79A14.95
15.70
None
None
CL  F 401 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6H0F_B_Y70B502_0
(IKAROS (IKZF1)
PROTEIN CEREBLON)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLU B 290
HIS B 356
TRP B 301
ASN B 269
GLY B 295
1.79A14.95
15.70
None
None
CL  B 401 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6H0F_B_Y70B502_0
(IKAROS (IKZF1)
PROTEIN CEREBLON)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLU F 290
HIS F 356
TRP F 301
ASN F 269
GLY F 295
1.80A14.95
15.70
None
None
CL  F 401 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6H0F_E_Y70E502_0
(IKAROS (IKZF1)
PROTEIN CEREBLON)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLU B 290
HIS B 356
TRP B 301
ASN B 269
GLY B 295
1.79A14.95
15.70
None
None
CL  B 401 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4TZU_B_Y70B505_1
(PROTEIN CEREBLON)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
HIS A6867
TRP A6922
PHE A6954
THR A6891
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4TZU_B_Y70B505_1
(PROTEIN CEREBLON)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
HIS C6867
TRP C6922
PHE C6954
THR C6891
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4TZU_B_Y70B505_1
(PROTEIN CEREBLON)		6wkq NSP16
(SARS-CoV-2)		4 / 7
HIS A6867
TRP A6922
PHE A6954
THR A6891
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4TZU_B_Y70B505_1
(PROTEIN CEREBLON)		6wkq NSP16
(SARS-CoV-2)		4 / 7
HIS C6867
TRP C6922
PHE C6954
THR C6891
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4TZU_B_Y70B505_1
(PROTEIN CEREBLON)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
HIS A6867
TRP A6922
PHE A6954
THR A6891
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2Z_C_Y70C151_1
(CEREBLON ISOFORM 4)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASN A 703
PHE A 753
TRP A 617
TYR A 619
1.71A9.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2Z_C_Y70C151_1
(CEREBLON ISOFORM 4)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
ASN A 703
PHE A 753
TRP A 617
TYR A 619
1.74A8.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2Z_C_Y70C151_1
(CEREBLON ISOFORM 4)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ASN A 703
PHE A 753
TRP A 617
TYR A 619
1.70A8.98
None